Literature DB >> 21505186

Inhibitory ITAM signaling traps activating receptors with the phosphatase SHP-1 to form polarized "inhibisome" clusters.

Séverine Pfirsch-Maisonnas1, Meryem Aloulou, Ting Xu, Julien Claver, Yutaka Kanamaru, Meetu Tiwari, Pierre Launay, Renato C Monteiro, Ulrich Blank.   

Abstract

The ability of immunoreceptor tyrosine-based activation motif (ITAM)-bearing receptors to inhibit, rather than activate, signaling by other receptors is a regulatory mechanism of immune homeostasis. However, it remains unclear how inhibitory ITAM (ITAMi) receptor signaling and Src homology 2 (SH2) domain-containing phosphatase-1 (SHP-1), which is recruited to ITAMs, target multiple heterologous activating responses without coaggregating with the associated activating receptors. We found that ITAMi signaling triggered by the binding of monomeric ligands to the type I immunoglobulin A (IgA) Fc receptor (FcαRI) induced its dynamic cosegregation with heterologous activating receptors, signaling effectors, and the inhibitory phosphatase SHP-1 into polarized intracellular clusters that we call "inhibisomes." Formation of inhibisomes was preceded by the recruitment of FcαRI and SHP-1 into lipid rafts. Cosegregation required the depolymerization of actin, which depended on SHP-1, and inhibisome formation was abolished by knockdown of SHP-1 and by actin-depolymerizing drugs. Thus, SHP-1- and actin depolymerization-dependent spatiotemporal compartmentalization of ITAMi-containing receptors into lipid rafts, regions associated with intracellular signaling, represents a key event in the integration of ITAMi-mediated inhibitory signals.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21505186     DOI: 10.1126/scisignal.2001309

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  35 in total

1.  Specific inactivation of two immunomodulatory SIGLEC genes during human evolution.

Authors:  Xiaoxia Wang; Nivedita Mitra; Ismael Secundino; Kalyan Banda; Pedro Cruz; Vered Padler-Karavani; Andrea Verhagen; Chris Reid; Martina Lari; Ermanno Rizzi; Carlotta Balsamo; Giorgio Corti; Gianluca De Bellis; Laura Longo; William Beggs; David Caramelli; Sarah A Tishkoff; Toshiyuki Hayakawa; Eric D Green; James C Mullikin; Victor Nizet; Jack Bui; Ajit Varki
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

2.  Positive and negative signaling through SLAM receptors regulate synapse organization and thresholds of cytolysis.

Authors:  Fang Zhao; Jennifer L Cannons; Mala Dutta; Gillian M Griffiths; Pamela L Schwartzberg
Journal:  Immunity       Date:  2012-06-07       Impact factor: 31.745

3.  Recombinant factor VIII Fc fusion protein drives regulatory macrophage polarization.

Authors:  Katalin Kis-Toth; Gaurav Manohar Rajani; Allison Simpson; Kate L Henry; Jennifer Dumont; Robert T Peters; Joe Salas; Christine Loh
Journal:  Blood Adv       Date:  2018-11-13

4.  Shifting FcγRIIA-ITAM from activation to inhibitory configuration ameliorates arthritis.

Authors:  Sanae Ben Mkaddem; Gilles Hayem; Friederike Jönsson; Elisabetta Rossato; Erwan Boedec; Tarek Boussetta; Jamel El Benna; Pierre Launay; Jean-Michel Goujon; Marc Benhamou; Pierre Bruhns; Renato C Monteiro
Journal:  J Clin Invest       Date:  2014-07-25       Impact factor: 14.808

5.  A Comprehensive Immunoreceptor Phosphotyrosine-based Signaling Network Revealed by Reciprocal Protein-Peptide Array Screening.

Authors:  Huadong Liu; Lei Li; Courtney Voss; Feng Wang; Juewen Liu; Shawn Shun-Cheng Li
Journal:  Mol Cell Proteomics       Date:  2015-04-23       Impact factor: 5.911

6.  Immunoglobulin A as an anti-inflammatory agent.

Authors:  R C Monteiro
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

7.  ITAM-coupled receptors inhibit IFNAR signaling and alter macrophage responses to TLR4 and Listeria monocytogenes.

Authors:  Linda Huynh; Lu Wang; Chao Shi; Kyung-Hyun Park-Min; Lionel B Ivashkiv
Journal:  J Immunol       Date:  2012-02-24       Impact factor: 5.422

Review 8.  Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond.

Authors:  P Mark Hogarth; Geoffrey A Pietersz
Journal:  Nat Rev Drug Discov       Date:  2012-03-30       Impact factor: 84.694

9.  Munc18-2 and syntaxin 3 control distinct essential steps in mast cell degranulation.

Authors:  Cristiana Brochetta; Ryo Suzuki; Francesca Vita; Maria Rosa Soranzo; Julien Claver; Lydia Celia Madjene; Tarik Attout; Joana Vitte; Nadine Varin-Blank; Giuliano Zabucchi; Juan Rivera; Ulrich Blank
Journal:  J Immunol       Date:  2013-12-09       Impact factor: 5.422

Review 10.  Role of FcγRIIIA (CD16) in IVIg-mediated anti-inflammatory function.

Authors:  Sanae Ben Mkaddem; Meryem Aloulou; Marc Benhamou; Renato C Monteiro
Journal:  J Clin Immunol       Date:  2014-04-13       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.